RxDoctor Payments Data

Nicole Britt

Family · Whiteville, NCNPI 1952878951

Payments from drug & device makers

$529in general payments, 2019–2025

Across 25 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$254
  • Novo Nordisk$80
  • Lilly USA, LLC$40
  • Exact Sciences$38
  • Amgen$25
  • Paratek Pharmaceuticals, Inc.$22
  • plus $71 from 4 others

What the payments were for

  • Food & beverage$529100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$529 in reported general payments places this provider in the 55th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$4,498
Medicare patients
41
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$42,437
FarxigaDapagliflozin Propanediol34$37,660
JardianceEmpagliflozin22$33,410
LinzessLinaclotide23$22,442
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$20,021
JanuviaSitagliptin Phosphate11$8,295
Spiriva RespimatTiotropium Bromide15$7,505
EdarbyclorAzilsartan Med/Chlorthalidone14$5,388
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,330
SymbicortBudesonide/Formoterol Fumarate13$2,888
Albuterol Sulfate HfaAlbuterol Sulfate81$2,441
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide30$2,037
Gabapentin156$1,718
Omega-3 Acid Ethyl Esters19$1,474
Atorvastatin Calcium160$1,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$80$42,43738 claims
Boehringer IngelheimJardiance, Spiriva Respimat$14$40,91537 claims
AstraZenecaFarxiga, Symbicort$254$40,54747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,522 family providers in North Carolina.

Other family in Whiteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →